Back to Search Start Over

Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin

Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin

Authors :
Aya Saiki
Michio Otsuki
Daisuke Tamada
Tetsuhiro Kitamura
Kosuke Mukai
Koichi Yamamoto
Iichiro Shimomura
Source :
Journal of the Endocrine Society
Publication Year :
2021
Publisher :
The Endocrine Society, 2021.

Abstract

Purpose Excessive aldosterone secretion causes a high risk of cardio-cerebrovascular events. Mineralocorticoid receptor antagonist (MRA) is 1 of the treatment strategies for primary aldosteronism (PA). However, current MRA treatment is insufficient because MRA-treated patients with suppressed plasma renin activity (PRA) Methods Thirty-four PA patients were recruited, and 24 patients (6 male, 18 female) completed this study. Serum potassium concentration was assessed every two months to adjust the dosage of MRA safely for 6 months. The primary outcomes were the changes in BP and UAE between baseline and 6 months. Results Systolic BP (SBP) and log10UAE decreased significantly as the daily dose of MRA increased. Diastolic BP (DBP) tended to decrease. We divided the PA patients into two groups (baseline PRA Conclusions The increase in MRA dosage improved BP and UAE in PA patients with suppressed PRA.

Details

ISSN :
24721972
Volume :
6
Database :
OpenAIRE
Journal :
Journal of the Endocrine Society
Accession number :
edsair.doi.dedup.....6aea4e0555729273cad12e9bf27bbacb
Full Text :
https://doi.org/10.1210/jendso/bvab174